OXB
Total Voting Rights
Oxford, UK - 01 May 2025: OXB (LSE: OXB) (the "Company"), a global quality and
innovation-led cell and gene therapy CDMO, today announces that
in accordance with the FCA's Disclosure
Guidance and Transparency Rule 5.6.1R, the Company's issued share
capital as at the close of business on 30 April 2025 consisted
of 105,998,460 ordinary shares of 50 pence
each ("Ordinary Shares"). There are no Ordinary Shares held in
treasury.
Accordingly, the total number of
voting rights in OXB at the date of this notice
is 105,998,460.
The above figure 105,998,460 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, OXB under the FCA's Disclosure Guidance and
Transparency Rules.
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary -
T: +44 (0) 1865 783 000 / E:
cosec@oxb.com
ICR
Healthcare:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE: OXB) is a
global quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell
and gene therapy, OXB has 30
years of experience in viral vectors; the driving
force behind the majority of cell and gene therapies. OXB
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in
lentivirus, adeno-associated virus (AAV), adenovirus and other
viral vector types. OXB's world-class capabilities span from
early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the TetraVecta™ system), dual plasmid system
for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging
cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing
facilities across Oxfordshire, UK, Lyon and Strasbourg, France and
near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.
